
Fluid decreased in vein occlusion, AMD, and DME on aflibercept 8 mg or faricimab.

Fluid decreased in vein occlusion, AMD, and DME on aflibercept 8 mg or faricimab.

Dilsher S. Dhoot, MD, FASRS, breaks down the Phase 3 SOL-1 results on intravitreal axitinib hydrogel (OTX-TKI) and aflibercept on vision maintenance.

November 12th 2026